Listed

Immucell Corp

ICCCNasdaqCIK 811641HealthcareFiscal year ends Dec 31

Reports and events: 337 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Immucell Corp, Reports and events
FiledFormWhat it isAccession number
2024-09-1713:49 ETSCHEDULE 13D/AOwnership report, active investor, amended0001744329-24-000005
2024-08-2716:32 ETSC 13DOwnership report, active investor0001193125-24-207799
2024-08-1316:05 ET10-QQuarterly reportPeriod 2024-06-300001213900-24-068245
2024-08-1316:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-24-068243
2024-07-0916:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-24-060121
2024-06-1413:38 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001213900-24-052776
2024-06-1411:33 ET8-K5.07 Shareholder vote results0001213900-24-052706
2024-06-0607:49 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-24-050197
2024-05-2216:50 ETSCHEDULE 13DOwnership report, active investor0001744329-24-000003
2024-05-1416:06 ET10-QQuarterly reportPeriod 2024-03-310001213900-24-042925
2024-05-1416:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-24-042926
2024-04-2609:00 ETDEF 14AProxy statementPeriod 2024-06-130001213900-24-036378
2024-04-0917:19 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001213900-24-031647
2024-04-0916:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-24-031589
2024-04-0116:05 ET10-KAnnual reportPeriod 2023-12-310001213900-24-028718
2024-03-0613:55 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001213900-24-020389
2024-02-2716:05 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001213900-24-017522
2024-02-2716:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-24-017520
2024-01-0816:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-24-001894
2023-11-1615:22 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001213900-23-087893
2023-11-1316:05 ET10-QQuarterly reportPeriod 2023-09-300001213900-23-086092
2023-11-1316:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-086101
2023-10-0516:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001013762-23-002136
2023-08-1016:06 ET10-QQuarterly reportPeriod 2023-06-300001213900-23-065595
2023-08-1016:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-065597
2023-07-2109:04 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001213900-23-058672
2023-07-1116:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-056198
2023-06-2913:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-23-052780
2023-06-2116:05 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001213900-23-050488
2023-05-1116:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-038528
2023-05-1116:05 ET10-QQuarterly reportPeriod 2023-03-310001213900-23-038529
2023-04-2810:13 ETDEF 14AProxy statementPeriod 2023-06-150001213900-23-033559
2023-04-0516:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-027540
2023-03-2916:05 ET10-KAnnual reportPeriod 2022-12-310001213900-23-024080
2023-02-2809:24 ET8-K5.02 Departure or appointment of officers or directors0001213900-23-015065
2023-02-2116:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-013281
2023-02-0117:25 ET8-K5.02 Departure or appointment of officers or directors0001213900-23-006754
2023-01-0916:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-23-001673
2022-11-2116:58 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-22-074266
2022-11-2116:06 ET10-QQuarterly reportPeriod 2022-09-300001213900-22-074215
2022-11-2109:49 ET10-Q/AQuarterly report, amendedPeriod 2022-06-300001213900-22-074052
2022-11-2109:44 ET10-Q/AQuarterly report, amendedPeriod 2022-03-310001213900-22-074049
2022-11-1016:24 ET8-K2.02 Results of operations; 4.02 Non-reliance on financial statements; 9.01 Financial statements and exhibits0001213900-22-071209
2022-10-0506:35 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-22-062089
2022-08-1716:37 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001213900-22-049025
2022-08-1116:07 ET10-QQuarterly reportPeriod 2022-06-300001213900-22-046861
2022-08-1116:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-22-046860
2022-07-2820:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001213900-22-042127
2022-07-0718:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001213900-22-037699
2022-06-2106:14 ET8-K/A5.07 Shareholder vote results0001213900-22-033723

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 13, 2026, 16:08 ET. Listed shows no prices and gives no investment advice.